Why merck Is Trending Today?

Merck has agreed to acquire Cidara Therapeutics in a $9.2 billion deal, aiming to bolster its portfolio of flu prevention treatments. The acquisition, which is expected to close in the second half of 2023, comes as Merck faces potential sales drops in its key cancer drug, Keytruda. Cidara's lead product, CD101, is a novel antiviral agent designed to prevent influenza, which could significantly benefit Merck's respiratory franchise. The deal, valued at $37 per share, represents a 105% premium to Cidara's closing price on February 24, 2023.

Merck acquires Verona Pharma for $10 billion.

Merck to Acquire Verona Pharma for $10 Billion